Literature DB >> 2201988

A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants.

R T Joffe1, W Singer.   

Abstract

Several studies suggest that small amounts of triiodothyronine (T3) will convert tricyclic antidepressant nonresponders into responders within a few days to a few weeks. As thyroxine (T4) is converted to T3 to have its physiological effect, it has been assumed that T4 would have a similar antidepressant effect to that of T3. We carried out a randomized, double-blind evaluation of the antidepressant-potentiating effect of T3 as compared with T4. Significantly more patients responded to 3 weeks of T3 as compared with T4 potentiation. Small but significant differential effects of the two thyroid hormones were noted on the Hamilton Rating Scale for Depression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201988     DOI: 10.1016/0165-1781(90)90029-5

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  22 in total

Review 1.  Bipolar depression: management options.

Authors:  Gin S Malhi; Philip B Mitchell; Shahzad Salim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression.

Authors:  Jeremy Barowsky; Thomas L Schwartz
Journal:  Psychiatry (Edgmont)       Date:  2006-07

Review 3.  Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin.

Authors:  Meritxell Tost; José Antonio Monreal; Antonio Armario; Juan David Barbero; Jesús Cobo; Clemente García-Rizo; Miquel Bioque; Judith Usall; Elena Huerta-Ramos; Virginia Soria; Javier Labad
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

4.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

Review 5.  Psychopharmacologic treatment of pediatric major depressive disorder.

Authors:  Khrista Boylan; Soledad Romero; Boris Birmaher
Journal:  Psychopharmacology (Berl)       Date:  2006-08-08       Impact factor: 4.530

Review 6.  Treatment of depression in older adults.

Authors:  Cássio M C Bottino; Ricardo Barcelos-Ferreira; Salma R I Ribeiz
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

7.  The Care of Patients With Complex Mood Disorders.

Authors:  Zachary A Cordner; Dean F MacKinnon; J Raymond DePaulo
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

Review 8.  Hormone treatment of depression.

Authors:  Russell T Joffe
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 9.  Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.

Authors:  Chia-Ming Chang; Soichiro Sato; Changsu Han
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

Review 10.  Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression.

Authors:  I Schweitzer; V Tuckwell
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.